Manufacturer Supply High Purity Atosiban Powder CAS No. 90779-69-4

• Powder: Yes
• Customized: Customized
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Children, Adult
• State: White Powder
• Purity: >99%
• Grade: Medicine Grade
• Appearance: White Powder
• CAS No: 90779-69-4
• Shelf Life: 2 Years
• Test Method: HPLC
• MOQ: 1kg
• Storage: Store Cool Dry Place
• Resource: Natural
• Mf: C43h67n11o12s2
• Transport Package: Ziplock Foil Bag
• Specification: 99%
• Trademark: Xi′an Frazer Biotech Co., Ltd.
• Origin: China
• Production Capacity: 2000kg/Month

Product Description

Manufacturer Supply High Purity Atosiban Powder CAS NO. 90779-69-4

Specification of Analysis

Items	Standards		Results
Appearance	White powder		Complies
Identification	By IR		Complies
	By HPLC		Complies
Solubility	Soluble in water		Complies
Amino Acid Composition	±10% of theoretical		Complies
MS	994.19±1.0		Complies
Water Content	≤ 5.0%		1.54%
Acetic Acid	≤ 15.0%		5.01%
Related Substances (Test Method A)	Any single impurity: ≤0.50%		0.19%
	Total impurities: ≤2.00 %		0.55%
Related Substances (Test Method B)	Any single impurity: ≤0.50%		0.13%
	Total impurities: ≤2.00 %		0.26%
Peptid Content	≥ 80.0%		91.46%
Reference Standard	In-house Standard

Product Description

Atosiban was introduced in the UK as an injectable inhibitor of preterm labor, a major cause of infant morbidity and mortality. This peptidic oxytocin analog is an antagonist of the vasopressin V1a receptor and of the oxytocin receptor which is found in dramatically increased concentration in the uterine myometrium of pregnant women near term. It competitively inhibited contractions in the pregnant guinea pig uterus induced by oxytocin and vasopressin. In a multicenter, double-blind, placebo-controlled trial, treatment with atosiban caused pregnancy prolongation for up to 7 days in women with more than 28 weeks of gestation. In a comparative clinical trial, atosiban showed a comparable tocolytic action (uterine relaxant) to ritodrine but the former was significantly better tolerated, especially with regards to maternal cardiovascular side effects. In healthy volunteers, plasma levels of atosiban decreased bi-exponentially with an initial and a terminal half-life of 21 min and 1.7h respectively.

Application: 

1.Atosiban is a nonapeptide, desamino-oxytocin analogue, and a competitive vasopressin/oxytocin receptor antagonist (VOTra).
2.Atosiban inhibits the oxytocin-mediated release of inositol trisphosphatefrom the myometrial cell membrane. 
3.Atosiban is useful in improving the pregnancy outcome of in vitro fertilization-embryo transfer (IVF-ET) in patients with repeated
implantation failure (RIF). The pregnancy rate improved from zero to 43.7%.

Product Name	CAS No.	Product Name	CAS No.
Lufenuron	103055-07-8	Toltrazuril	69004-03-1
Nitenpyram	120738-89-8	Praziquantel/Biltricide	55268-74-1
Fenbendazole	43210-67-9	Tetramisole Hcl	5086-74-8
Levamisole	14769-73-4	Ponazuril	9004-4-2
Diclazuril	101831-37-2	Florfenicol	73231-34-2
Ivermectin	70288-86-7	Enrofloxacin Hcl	112732-17-9
Albendazole	54965-21-8	Mebendazole	31431-39-7